PlaqueTec, a Cambridge, UK-based company pioneering the development of a biomarker-based approach to transform the understanding of coronary artery disease (CAD), has appointed Dr Tim Brears as Chief Executive.
Dr Brears until recently was Chief Executive of Xention, a developer of drugs for the control of atrial fibrillation, which he founded in 2002. Prior to this, he was Chief Executive of Gendaq, a gene-regulation company, which was acquired by Sangamo Biosciences in 2001.
From 1993 to 1999 he was Director of Licensing at Ciba-Geigy (later Novartis) Agribusiness in Research Triangle Park, North Carolina, US.
